538 related articles for article (PubMed ID: 31967735)
21. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
[TBL] [Abstract][Full Text] [Related]
22. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Wang ES
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
[TBL] [Abstract][Full Text] [Related]
23. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
24. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
25. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Pratz KW; Sato T; Murphy KM; Stine A; Rajkhowa T; Levis M
Blood; 2010 Feb; 115(7):1425-32. PubMed ID: 20007803
[TBL] [Abstract][Full Text] [Related]
26. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Manley PW; Caravatti G; Furet P; Roesel J; Tran P; Wagner T; Wartmann M
Biochemistry; 2018 Sep; 57(38):5576-5590. PubMed ID: 30148617
[TBL] [Abstract][Full Text] [Related]
28. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Hogan FL; Williams V; Knapper S
Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
[TBL] [Abstract][Full Text] [Related]
29. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
[TBL] [Abstract][Full Text] [Related]
30. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
Daver N; Venugopal S; Ravandi F
Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
[TBL] [Abstract][Full Text] [Related]
31. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
Yamawaki K; Shiina I; Murata T; Tateyama S; Maekawa Y; Niwa M; Shimonaka M; Okamoto K; Suzuki T; Nishida T; Abe R; Obata Y
Sci Rep; 2021 Nov; 11(1):22678. PubMed ID: 34811450
[TBL] [Abstract][Full Text] [Related]
32. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
33. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
34. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
Garitano-Trojaola A; Sancho A; Götz R; Eiring P; Walz S; Jetani H; Gil-Pulido J; Da Via MC; Teufel E; Rhodes N; Haertle L; Arellano-Viera E; Tibes R; Rosenwald A; Rasche L; Hudecek M; Sauer M; Groll J; Einsele H; Kraus S; Kortüm MK
Commun Biol; 2021 Jun; 4(1):799. PubMed ID: 34172833
[TBL] [Abstract][Full Text] [Related]
35. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
36. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
[TBL] [Abstract][Full Text] [Related]
37. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
Schlenk RF; Kayser S
Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
[TBL] [Abstract][Full Text] [Related]
38. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
[TBL] [Abstract][Full Text] [Related]
39. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Fathi AT; Chabner BA
Oncologist; 2011; 16(8):1162-74. PubMed ID: 21765192
[TBL] [Abstract][Full Text] [Related]
40. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
